Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Jun Toyohara; Danielle Vugts; Oliver C Kiss; Sergio Todde; Xiang-Guo Li; Zhibo Liu; Zhi Yang; Nic Gillings; Emiliano Cazzola; Wiktor Szymanski; Nick van der Meulen; Raymond Reilly; Carlotta Taddei; Ralf Schirrmacher; Zijing Li; Yohannes Jorge Lagebo; Naoual Bentaleb; Marta de Souza Albernaz; Suzanne Lapi; Caterina Ramogida; Archana Mukherjee; Javier Ajenjo; Winnie Deuther-Conrad; Cécile Bourdeau

doi:10.1186/s41181-024-00268-w

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

EJNMMI Radiopharm Chem. 2024 May 16;9(1):42. doi: 10.1186/s41181-024-00268-w.

Authors

Jun Toyohara¹, Danielle Vugts², Oliver C Kiss³, Sergio Todde⁴, Xiang-Guo Li⁵, Zhibo Liu⁶, Zhi Yang⁷, Nic Gillings⁸, Emiliano Cazzola⁹, Wiktor Szymanski¹⁰, Nick van der Meulen¹¹, Raymond Reilly¹², Carlotta Taddei¹³, Ralf Schirrmacher¹⁴, Zijing Li¹⁵, Yohannes Jorge Lagebo¹⁶, Naoual Bentaleb¹⁷, Marta de Souza Albernaz¹⁸, Suzanne Lapi¹⁹, Caterina Ramogida^{20

21}, Archana Mukherjee²², Javier Ajenjo²³, Winnie Deuther-Conrad²⁴, Cécile Bourdeau²⁵

Affiliations

¹ Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
² Amsterdam University Medical Center, Amsterdam, The Netherlands.
³ Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. o.kiss@hzdr.de.
⁴ University of Milano-Bicoccia, Tecnomed Foundation, Monza, Italy.
⁵ Turku PET Centre and Department of Chemistry, and InFLAMES Research Flagship Center, University of Turku, Turku, Finland.
⁶ Peking University, Beijing, China.
⁷ Peking University Cancer Hospital & Institute, Beijing, China.
⁸ Copenhagen University Rigshospitalet, Copenhagen, Denmark.
⁹ Sacro Cuore Hospital, Verona, Italy.
¹⁰ University of Groningen, Groningen, The Netherlands.
¹¹ Paul Scherrer Institute (PSI), Villigen, Switzerland.
¹² University of Toronto, Toronto, Canada.
¹³ Life Molecular Imaging GmbH, Berlin, Germany.
¹⁴ University of Alberta, Edmonton, Canada.
¹⁵ Xiamen University, Xiamen, China.
¹⁶ Addis Ababa University, Addis Ababa, Ethiopia.
¹⁷ National Center for Nuclear Energy, Science and Technology-CNESTEN, Rabat, Morocco.
¹⁸ University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
¹⁹ University of Alabama at Birmingham, Birmingham, USA.
²⁰ Simon Fraser University, Burnaby, Vancouver, Canada.
²¹ TRIUMF, Burnaby, Vancouver, Canada.
²² Bhabha Atomic Research Center and Homi Bhabha National Institute, Mumbai, India.
²³ Molecular Imaging Program at Stanford (MIPS), Dept of Radiology, School of Medicine, Stanford University, Stanford, CA), USA.
²⁴ Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Leipzig, Germany.
²⁵ GIP Arronax, Nantes, France.

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

Main body: This selection of highlights provides commentary on 24 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

Conclusion: Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Keywords: Highlight articles; Nuclear medicine; Radiochemistry; Radiopharmaceutical sciences; Radiopharmacy; Trends in radiopharmaceutical sciences.

Publication types

Review